HilleVax (HLVX) Competitors $1.95 -0.01 (-0.51%) (As of 12/16/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HLVX vs. ENGN, VALN, VYGR, JSPR, FDMT, FATE, ITOS, ATYR, TNYA, and CCCCShould you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include enGene (ENGN), Valneva (VALN), Voyager Therapeutics (VYGR), Jasper Therapeutics (JSPR), 4D Molecular Therapeutics (FDMT), Fate Therapeutics (FATE), iTeos Therapeutics (ITOS), Atyr PHARMA (ATYR), Tenaya Therapeutics (TNYA), and C4 Therapeutics (CCCC). These companies are all part of the "biological products, except diagnostic" industry. HilleVax vs. enGene Valneva Voyager Therapeutics Jasper Therapeutics 4D Molecular Therapeutics Fate Therapeutics iTeos Therapeutics Atyr PHARMA Tenaya Therapeutics C4 Therapeutics HilleVax (NASDAQ:HLVX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends. Does the MarketBeat Community believe in HLVX or ENGN? enGene received 4 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 100.00% of users gave enGene an outperform vote while only 58.82% of users gave HilleVax an outperform vote. CompanyUnderperformOutperformHilleVaxOutperform Votes1058.82% Underperform Votes741.18% enGeneOutperform Votes14100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of HLVX or ENGN? 86.4% of HilleVax shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 71.1% of HilleVax shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is HLVX or ENGN more profitable? enGene's return on equity of -66.38% beat HilleVax's return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -67.27% -51.99% enGene N/A -66.38%-56.00% Do analysts recommend HLVX or ENGN? HilleVax presently has a consensus price target of $3.00, indicating a potential upside of 53.85%. enGene has a consensus price target of $30.38, indicating a potential upside of 382.14%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00enGene 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Does the media prefer HLVX or ENGN? In the previous week, enGene had 1 more articles in the media than HilleVax. MarketBeat recorded 2 mentions for enGene and 1 mentions for HilleVax. HilleVax's average media sentiment score of 1.87 beat enGene's score of 1.40 indicating that HilleVax is being referred to more favorably in the media. Company Overall Sentiment HilleVax Very Positive enGene Positive Which has more volatility & risk, HLVX or ENGN? HilleVax has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.78, meaning that its stock price is 178% less volatile than the S&P 500. Which has better valuation & earnings, HLVX or ENGN? enGene is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$123.57M-$3.10-0.63enGeneN/AN/A-$99.92M-$1.63-3.87 SummaryenGene beats HilleVax on 10 of the 16 factors compared between the two stocks. Ad ProsperityPubGrab these five dividend cheat sheetsWould you like a simple set of guidelines for building a rock solid dividend portfolio? Including the two specific tickers I just put $50k into? Well, it’s all included in these FIVE Dividend Cheat Sheets>> You can grab your FREE, laminated copies right here << Get HilleVax News Delivered to You Automatically Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HLVX vs. The Competition Export to ExcelMetricHilleVaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.12M$2.96B$4.97B$9.33BDividend YieldN/A1.85%4.78%4.04%P/E Ratio-0.6345.34134.8117.59Price / SalesN/A353.331,235.5083.14Price / CashN/A182.1340.8738.32Price / Book0.363.924.924.93Net Income-$123.57M-$41.89M$117.85M$225.54M7 Day Performance-1.02%-3.82%13.24%-1.11%1 Month Performance6.56%6.89%16.48%5.67%1 Year Performance-86.68%22.00%35.63%22.97% HilleVax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HLVXHilleVax2.8258 of 5 stars$1.95-0.5%$3.00+53.8%-86.7%$97.12MN/A-0.6390Positive NewsENGNenGene3.1614 of 5 stars$8.44-2.4%$30.38+259.9%-14.7%$373.22MN/A0.0031Positive NewsGap UpVALNValneva2.1596 of 5 stars$4.33+4.6%$18.50+327.3%-64.6%$351.81M$165.52M0.00700VYGRVoyager Therapeutics4.654 of 5 stars$6.41-0.6%$17.00+165.2%-18.8%$350.18M$250.01M9.08100JSPRJasper Therapeutics2.4456 of 5 stars$22.35-0.6%$73.38+228.3%+343.4%$335.25MN/A0.0020FDMT4D Molecular Therapeutics2.7267 of 5 stars$7.17-2.4%$42.13+487.5%-63.5%$331.47M$20.72M-2.62201Short Interest ↑FATEFate Therapeutics3.7204 of 5 stars$2.76+4.2%$6.75+144.6%-33.8%$314.34M$63.53M0.00550Short Interest ↑ITOSiTeos Therapeutics3.7424 of 5 stars$8.38+0.7%$31.50+275.9%-28.4%$306.16M$35M-2.6490ATYRAtyr PHARMA2.6224 of 5 stars$3.62+7.7%$19.25+431.8%N/A$303.86M$350,000.00-3.8756TNYATenaya Therapeutics3.8339 of 5 stars$3.77+5.3%$17.33+359.8%+38.5%$298.66MN/A-2.71110Gap UpHigh Trading VolumeCCCCC4 Therapeutics1.5381 of 5 stars$4.21-4.8%$10.00+137.5%-12.9%$297.18M$20.76M-2.60150Gap Up Related Companies and Tools Related Companies ENGN Competitors VALN Competitors VYGR Competitors JSPR Competitors FDMT Competitors FATE Competitors ITOS Competitors ATYR Competitors TNYA Competitors CCCC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HLVX) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
